Q2 Earnings Estimate for ICON Public Issued By William Blair

ICON Public Limited (NASDAQ:ICLR - Free Report) - William Blair cut their Q2 2025 earnings per share estimates for shares of ICON Public in a report issued on Thursday, May 1st. William Blair analyst M. Smock now anticipates that the medical research company will post earnings per share of $3.06 for the quarter, down from their previous forecast of $3.18. William Blair has a "Outperform" rating on the stock. The consensus estimate for ICON Public's current full-year earnings is $13.38 per share. William Blair also issued estimates for ICON Public's Q3 2025 earnings at $3.17 EPS, Q4 2025 earnings at $3.33 EPS, FY2025 earnings at $12.62 EPS, Q1 2026 earnings at $3.13 EPS, Q2 2026 earnings at $3.27 EPS and Q3 2026 earnings at $3.51 EPS.

Other equities research analysts have also recently issued reports about the company. Mizuho decreased their price objective on ICON Public from $238.00 to $200.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Barclays decreased their price target on shares of ICON Public from $165.00 to $155.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. TD Cowen lowered shares of ICON Public from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $254.00 to $157.00 in a research note on Monday, April 14th. Robert W. Baird decreased their target price on shares of ICON Public from $192.00 to $160.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Finally, JPMorgan Chase & Co. lowered shares of ICON Public from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $265.00 to $150.00 in a report on Tuesday, April 29th. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $215.33.

ICON Public Stock Down 1.1 %

ICON Public stock traded down $1.56 during mid-day trading on Monday, reaching $136.92. 291,965 shares of the company were exchanged, compared to its average volume of 1,000,720. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. The firm has a market cap of $11.06 billion, a P/E ratio of 14.37, a PEG ratio of 1.86 and a beta of 1.23. The business has a fifty day moving average of $160.92 and a 200 day moving average of $191.85. ICON Public has a 12-month low of $133.28 and a 12-month high of $347.72.

ICON Public (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical research company reported $3.19 earnings per share for the quarter, topping analysts' consensus estimates of $3.17 by $0.02. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The company had revenue of $2 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same period in the prior year, the firm earned $3.47 earnings per share. The firm's revenue for the quarter was down 4.3% compared to the same quarter last year.

Institutional Investors Weigh In On ICON Public

Several hedge funds have recently added to or reduced their stakes in ICLR. Tributary Capital Management LLC increased its stake in shares of ICON Public by 116.1% in the 4th quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company's stock valued at $828,000 after purchasing an additional 2,122 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock worth $91,000 after acquiring an additional 169 shares during the period. Entropy Technologies LP boosted its holdings in ICON Public by 472.2% in the 4th quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company's stock valued at $1,295,000 after purchasing an additional 5,095 shares during the last quarter. Natixis Advisors LLC increased its stake in ICON Public by 6.7% during the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company's stock worth $37,279,000 after acquiring an additional 11,177 shares during the last quarter. Finally, Motley Fool Wealth Management LLC lifted its position in ICON Public by 2.3% in the fourth quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company's stock valued at $13,342,000 after buying an additional 1,466 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.